Affordable Access

Access to the full text

Strategies For Targeting Chronic Myeloid Leukaemia Stem Cells

Authors
  • Carrà, Giovanna1
  • Cartellà, Antonio1
  • Maffeo, Beatrice1
  • Morotti, Alessandro1
  • 1 Department Of Clinical And Biological Sciences, University Of Turin, Orbassano, 10043 , (Italy)
Type
Published Article
Journal
Blood and Lymphatic Cancer: Targets and Therapy
Publisher
Dove
Publication Date
Nov 06, 2019
Volume
9
Pages
45–52
Identifiers
DOI: 10.2147/BLCTT.S228815
PMID: 31807112
PMCID: PMC6842740
Source
PubMed Central
Keywords
License
Green

Abstract

Chronic Myeloid Leukaemia is a myeloproliferative disorder driven by the t(9;22) chromosomal translocation coding for the chimeric protein BCR-ABL. CML treatment represents the paradigm of molecular therapy of cancer. Since the development of the tyrosine kinase inhibitor of the BCR-ABL kinase, the clinical approach to CML has dramatically changed, with a stunning improvement in the quality of life and response rates of patients. However, it remains clear that tyrosine kinase inhibitors (TKIs) are unable to target the most immature cellular component of CML, the CML stem cell. This review summarizes new insights into the mechanisms of resistance to TKIs.

Report this publication

Statistics

Seen <100 times